Bortezomib

• Background:

  Potent and selective proteasome inhibitor (Ki=0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50=7 nM). Inhibits TNF synthesis and FGF-induced angiogenesis. Reversible. Cell permeable.

• Description:

  Proteasome inhibitor

• Product Name Alternative:

  B-[ (1R) -3-Methyl-1-[[ (2S) -1-oxo-3-phenyl-2-[ (2-pyrazinylcarbonyl) amino]propyl]amino]butyl]boronic Acid; [ (1R) -3-Methyl-1-[[ (2S) -1-oxo-3-phenyl-2-[ (pyrazinylcarbonyl) amino]propyl]amino]butyl]boronic Acid; Velcade; Radiciol; NSC 681239; DPBA; LDP 341; MG 341; mlN 341; NSC 681239; PS 314; PS 341; Radiciol; Velcade

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cancer | Apoptosis | Cancer Growth Inhibitors | Proteasome Inhibitors

• Purity:

  >98%

• Weight:

  0.025

• Format:

  White Powder

• Solubility:

  Soluble in 50 mg/ml DMSO, 35 mg/ml Ethanol

• Molecular Formula:

  C19H25BN4O4

• Molecular Weight:

  384.2

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Adams J., et al. (1999) Cancer Res. 59: 2615. 2. Williams S., et al. (2003) Mol. Cancer Ther. 2: 835.

• CAS Number:

  179324-69-7